Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 397

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer

Ebata, T, Hirano, S, Konishi, M, Uesaka, K, Tsuchiya, Y, Ohtsuka, M, Kaneoka, Y, Yamamoto, M, Ambo, Y, Shimizu, Y, Ozawa, F, Fukutomi, A, Ando, M, Nimura, Y, Nagino, M, Nakamori, S, Ajiki, T, Baba, H, Yamaguchi, R, Kawai, M, Nagano, H, Miura, F, Arai, T, Nishiwaki, Y, Kawasaki, S, Shinchi, H, Shimoda, M, Yamamoto, Y, Endo, I, Isaji, S, Otsubo, T, Ishihara, S, Takahara, T, Shimada, M, Unno, M, Imamura, M, Ohkochi, N, Murakami, Y, Fujimoto, J, Ikuta, S, Fujino, Y, Uebayashi, M, Ishiyama, S, Takakura, N, Kumamoto, Y, Kato, T, Yoshioka, I, Uemoto, S, Yanaga, K·2018·British Journal of Surgery

Abstract

Background: Although some retrospective studies have suggested the value of adjuvant therapy, no recommended standard exists in bile duct cancer. The aim of this study was to test the hypothesis that adjuvant gemcitabine chemotherapy would improve survival probability in resected bile duct cancer. Methods: This was a randomized phase III trial. Patients with resected bile duct cancer were assigned randomly to gemcitabine and observation groups, which were balanced with respect to lymph node status, residual tumour status and tumour location. Gemcitabine was given intravenously at a dose of 1000 mg/m2, administered on days 1, 8 and 15 every 4 weeks for six cycles. The primary endpoint was overall survival, and secondary endpoints were relapse-free survival, subgroup analysis and toxicity. Results: Some 225 patients were included (117 gemcitabine, 108 observation). Baseline characteristics were well balanced between the gemcitabine and observation groups. There were no significant differences in overall survival (median 62·3 versus 63·8 months respectively; hazard ratio 1·01, 95 per cent c.i. 0·70 to 1·45; P = 0·964) and relapse-free survival (median 36·0 versus 39·9 months; hazard ratio 0·93, 0·66 to 1·32; P = 0·693). There were no survival differences between the two groups in subsets stratified by lymph node status and margin status. Although haematological toxicity occurred frequently in the gemcitabine group, most toxicities were transient, and grade 3/4 non-haematological toxicity was rare. Conclusion: The survival probability in patients with resected bile duct cancer was not significantly different between the gemcitabine adjuvant chemotherapy group and the observation group. Registration number: UMIN 000000820 (http://www.umin.ac.jp/).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/bjs.10776

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 18 references

Cited by

See all 397

Metadata

Authors
Ebata, T., Hirano, S., Konishi, M., Uesaka, K., Tsuchiya, Y., Ohtsuka, M., Kaneoka, Y., Yamamoto, M., Ambo, Y., Shimizu, Y., Ozawa, F., Fukutomi, A., Ando, M., Nimura, Y., Nagino, M., Nakamori, S., Ajiki, T., Baba, H., Yamaguchi, R., Kawai, M., Nagano, H., Miura, F., Arai, T., Nishiwaki, Y., Kawasaki, S., Shinchi, H., Shimoda, M., Yamamoto, Y., Endo, I., Isaji, S., Otsubo, T., Ishihara, S., Takahara, T., Shimada, M., Unno, M., Imamura, M., Ohkochi, N., Murakami, Y., Fujimoto, J., Ikuta, S., Fujino, Y., Uebayashi, M., Ishiyama, S., Takakura, N., Kumamoto, Y., Kato, T., Yoshioka, I., Uemoto, S., & Yanaga, K.
Venue
British Journal of Surgery
Published
2018-02
Volume
105
Issue
3
Pages
192-202
ISSN
  • 0007-1323 (ISSN-L)
  • 1365-2168
OpenAlex
W2790277876
Cited by
397
References
18
FWCI
36.29
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer. https://app.cochat.ai/papers/10.1002/bjs.10776
The paper
Ebata, T., Hirano, S., Konishi, M., Uesaka, K., Tsuchiya, Y., Ohtsuka, M., Kaneoka, Y., Yamamoto, M., Ambo, Y., Shimizu, Y., Ozawa, F., Fukutomi, A., Ando, M., Nimura, Y., Nagino, M., Nakamori, S., Ajiki, T., Baba, H., Yamaguchi, R., . . . Yanaga, K. (2018). Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer. British Journal of Surgery. https://doi.org/10.1002/bjs.10776

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.